GlobalData on MSN9d
Cofactor’s cancer biomarker test outshines standard ICI predictive tests
The test improved prediction of patient benefit from anti-PD-1 immune checkpoint inhibitors (ICIs) as a monotherapy and with ...
Yahoo Finance11d
Caris Life Sciences Receives FDA Approval for MI Cancer Seek™ as a Companion Diagnostic (CDx) Test
microsatellite instability (MSI), tumor mutational burden (TMB) in patients with previously diagnosed solid tumors, and copy ...
precisionmedicineonline5d
Marengo Therapeutics Advancing Bispecific Antibody to Phase II After Positive First-in-Human Data
A Phase I study of invikafusp alfa presented at SITC provided the rationale to enroll patients with TMB-high, MSI-high, and virus-associated tumors in Phase II.
GlobalData on MSN11d
Caris Life Sciences nabs FDA approval for multicancer companion diagnostic
The company’s MI Cancer Seek is approved as a companion diagnostic for multiple cancer therapies, including MSD’s Keytruda, ...
Bengaluru start-up strives to bridge India’s genomics data gap to aid precision oncology
While there have been substantial advancements in the field of oncology and the treatment of the disease, keeping the cancer ...
healthandpharma9d
FDA Approves MI Cancer Seek Test as a Groundbreaking Tool for Targeted Cancer Therapy
The FDA has approved Caris Life Sciences’ MI Cancer Seek, a pioneering diagnostic test combining Whole Exome and Whole ...
Business Wire10d
Cofactor Genomics Publishes Clinical Validation of OncoPrism-HNSCC, a Test Leveraging Novel RNA Modeling Technology to Predict Response to Immunotherapy
The multicenter study reports a 300% improvement in specificity over PD-L1 CPS and a 400% improvement in sensitivity over Tumor Mutational Burden (TMB) in predicting patient benefit from ICI.